We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
5 own
14 watching
Current Price
$0
$-0.05
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
733.81M
52-Week High
21.87
52-Week Low
9.4286
Average Volume
0.04M
Dividend Yield
0.04
P/E Ratio
21.7527
Market Capitalization733.81M
52-Week High21.87
52-Week Low9.4286
Average Volume0.04M
Dividend Yield0.04
P/E Ratio21.7527
What does the Stockal+Disclaimer.pdf do?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Boston, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
21days ago
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that positive preclinical data from four new pipeline programs will be featured at poster presentations at the Society for...
Ticker Report
1month ago
Adicet Bio, Inc. (NASDAQ:ACET Get Rating) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totalling 3,960,000 shares, a growth of 30.3% from the September 15th total of 3,040,000 shares. Currently, 15.0% of the company...
Zolmax
1month ago
Adicet Bio, Inc. (NASDAQ:ACET Get Rating) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 3,960,000 shares, a growth of 30.3% from the September 15th total of 3,040,000 shares. Currently, 15.0% of the shares...
Business Wire
1month ago
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for...
Business Wire
7 months ago
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that updated safety and efficacy data from the Phase 1 study of ADI-001 for the...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.05
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00